Plasmablastic lymphoma(PBL)is an aggressive lymphoma with limited treatment strategies.Tuberculosis(TB)infection poses a high risk for patients with hematologic malignancies,especially those treated with immune agents...Plasmablastic lymphoma(PBL)is an aggressive lymphoma with limited treatment strategies.Tuberculosis(TB)infection poses a high risk for patients with hematologic malignancies,especially those treated with immune agents but were never reported postdaratumumab treatment.Herein,we reported a TB infection in a 57-year-old male diagnosed with HIV-negative PBL receiving daratumumab-based treatment,who showed atypical lung infection and yielded Mycobacterium tuberculosis and cytomegalovirus(CMV)in the bronchoalveolar lavage fluid.Anti-TB therapy was administered,and the following daratumumab treatment was complete with good tolerance.In this case,we demonstrated that TB infection might occur after daratumumab therapy,and adequate attention should be paid to atypical symptoms.展开更多
基金the fundings from the National Natural Science Foundation of China(81873427 and 82070217 to Dr.Jia Wei)CHEN XIAO-PING Foundation for the Development of Science and Technology of Hubei Province(CXPJJH12000009-113,to Dr.Jia Wei).
文摘Plasmablastic lymphoma(PBL)is an aggressive lymphoma with limited treatment strategies.Tuberculosis(TB)infection poses a high risk for patients with hematologic malignancies,especially those treated with immune agents but were never reported postdaratumumab treatment.Herein,we reported a TB infection in a 57-year-old male diagnosed with HIV-negative PBL receiving daratumumab-based treatment,who showed atypical lung infection and yielded Mycobacterium tuberculosis and cytomegalovirus(CMV)in the bronchoalveolar lavage fluid.Anti-TB therapy was administered,and the following daratumumab treatment was complete with good tolerance.In this case,we demonstrated that TB infection might occur after daratumumab therapy,and adequate attention should be paid to atypical symptoms.
